UNIGE document Scientific Article
previous document  unige:19086  next document
add to browser collection

Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice

Merani, S.
Truong, W.
Emamaullee, J. A.
Knudsen, L. B.
Shapiro, A M. J.
Published in Endocrinology. 2008, vol. 149, no. 9, p. 4322-4328
Abstract The current scarcity of high-quality deceased pancreas donors prevents widespread application of islet transplantation for treatment of labile type 1 diabetes mellitus. Opportunities for the improvement of current techniques include optimization of islet isolation and purification, use of culture with pharmacological insulinotropic agents, strategies to reduce graft rejection and inflammation, and the search for alternative insulin producing tissue. Here, we report our findings on the efficacy of the long-acting human glucagon-like peptide 1 analog, liraglutide, in a mouse model of marginal mass islet transplantation. Liraglutide was administered (200 microg/kg sc twice daily) after a marginal mass syngeneic islet transplant in streptozotocin-induced diabetic BALB/c mice. Time-to-normoglycemia was significantly shorter in liraglutide-treated animals (median 1 vs. 7 d; P = 0.0003), even in recipients receiving sirolimus (median 1 vs. 72.5 d; P < 0.0001). Liraglutide-treated animals also demonstrated improved glucose tolerance as assessed by an ip glucose tolerance test. Liraglutide discontinuation at postoperative d 90 resulted in diminished glucose tolerance during the ip glucose tolerance test, whereas a late-start liraglutide therapy 90 d after transplant resulted in no improvement. These findings suggest that liraglutide therapy mediates early and late insulinotropic effects. In accord with this hypothesis, insulin/terminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphosphate nick end labeling fluorescence microscopy showed reduced transplanted beta-cell apoptosis in liraglutide-treated recipients 48 h after transplant. In addition, liraglutide resulted in improved glucose-dependent insulin secretion. Overall, our data show that liraglutide has a beneficial impact on the engraftment and function of syngeneic islet transplants in mice, when administered continuously starting on the day of transplant.
Keywords AnimalsApoptosis/drug effectsDelayed-Action PreparationsDiabetes Mellitus, Experimental/chemically induced/therapyDrug Evaluation, PreclinicalGlucagon-Like Peptide 1/*analogs & derivatives/pharmacology/therapeuticUseGlucose/*metabolismGlucose Intolerance/therapyGraft Rejection/prevention & controlHomeostasis/*drug effectsIslets of Langerhans/*drug effects/metabolism*Islets of Langerhans Transplantation/methods/rehabilitationMiceMice, Inbred BALB CSatiety Response/drug effectsStreptozocin
PMID: 18511515
Full text
Article - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://endo.endojournals.org/content/149/9/4322.full.pdf
Research group Transplantation et hépatologie (905)
(ISO format)
MERANI, S. et al. Liraglutide, a long-acting human glucagon-like peptide 1 analog, improves glucose homeostasis in marginal mass islet transplantation in mice. In: Endocrinology, 2008, vol. 149, n° 9, p. 4322-4328. https://archive-ouverte.unige.ch/unige:19086

151 hits

1 download


Deposited on : 2012-03-27

Export document
Format :
Citation style :